Moors & Cabot Inc. lowered its stake in shares of Qiagen N.V. (NYSE:QGEN – Free Report) by 26.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 250,461 shares of the company’s stock after selling 89,000 shares during the quarter. Moors & Cabot Inc. owned approximately 0.12% of Qiagen worth $10,960,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Amundi increased its position in Qiagen by 12.4% in the first quarter. Amundi now owns 4,757,681 shares of the company’s stock worth $190,498,000 after buying an additional 524,959 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Qiagen in the first quarter valued at $14,647,000. Troluce Capital Advisors LLC purchased a new position in shares of Qiagen during the 1st quarter valued at $14,514,000. Hsbc Holdings PLC purchased a new position in shares of Qiagen during the 1st quarter valued at $12,916,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Qiagen by 20.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company’s stock worth $66,649,000 after acquiring an additional 286,665 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on the company. UBS Group boosted their price objective on Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Friday. Jefferies Financial Group reiterated a “buy” rating and set a $48.00 target price on shares of Qiagen in a research report on Thursday, August 6th. Robert W. Baird lifted their target price on shares of Qiagen from $50.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, October 22nd. JPMorgan Chase & Co. lowered shares of Qiagen from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $55.00 to $52.00 in a research report on Thursday, October 22nd. Finally, Citigroup restated a “neutral” rating and set a $52.00 price target (up from $45.00) on shares of Qiagen in a research note on Monday, October 26th. Four equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $46.34.
Qiagen Stock Up 0.1%
Shares of NYSE QGEN opened at $49.92 on Monday. The company has a quick ratio of 2.14, a current ratio of 2.63 and a debt-to-equity ratio of 0.43. The firm’s fifty day moving average is $46.51 and its 200 day moving average is $42.65. The company has a market cap of $10.29 billion, a price-to-earnings ratio of 27.28, a PEG ratio of 4.00 and a beta of 0.56. Qiagen N.V. has a 52 week low of $32.53 and a 52 week high of $57.81.
Qiagen (NYSE:QGEN – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.02. Qiagen had a return on equity of 14.70% and a net margin of 18.19%. The company had revenue of $547.87 million for the quarter, compared to analysts’ expectations of $538.61 million. During the same period in the prior year, the firm earned $0.61 earnings per share. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. On average, equities research analysts expect that Qiagen N.V. will post 2.44 earnings per share for the current year.
Qiagen Company Profile
QIAGEN is a life sciences company that develops technologies used to prepare and analyze biological samples. Its products help researchers and clinicians extract and process DNA, RNA and proteins from samples such as blood, tissue and other biological materials. The company offers laboratory consumables, instruments and software for molecular diagnostics and life sciences research, as well as applications in pharmaceutical research and applied testing. Its portfolio includes sample-preparation kits, molecular testing assays and platforms for PCR, digital PCR and next-generation sequencing.
Read More
- Five stocks we like better than Qiagen
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN – Free Report).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
